Epigenetic therapy shows promise against treatment-resistant AML
Researchers at The University of Texas MD Anderson Cancer Center have discovered that an investigational epigenetic therapy remained effective in treatment-resistant acute myeloid leukemia (AML) by activating the Hippo pathway, a tumor-suppressing pathway linked to cancer growth